Note this refers to a 10% royalty paid to RAC for the out-licensing of bisantrene, which is not necessarily the same royalty paid to RAC holders.
I actually think 10% is a very conservative estimate, and as far as I can tell they make no mention of upfronts and milestones that will surely be incorporated into any transaction.
There are probably 5 super conservative estimates in that screen shot alone:
- no upfronts or milestones
- 10% royalty
- 32% success rate (based on industry-accepted ranges that do not account for the clinical history of bisantrene)
- target market that excludes the highest anthracycline market in the world (and every other jurisdiction outside the US and Europe)
- 10% peak market penetration
I find the 10% market penetration most peculiar. If you assume for a second that CPACs is demonstrated unequivocally in the clinical trials, you're telling me that 90% of the market are going to ignore a therapy that is proven to not only improve the rate of cancer-killing, but protects the patients from cardiotoxic harm. That is a ridiculous assumption, and is antithetical to the core principles of medicine in the first place. I personally think if you assume that bisantrene makes it to the market, your uptake rates have to be far higher, AT LEAST 50% but possibly far higher. I just cannot see a physician in the world that refuses to give bisantrene to patients assuming it does actually protect from cardiotoxicity.
Of course I understand why such conservative estimates have to be used, because as mentioned many times on this forum, the numbers genuinely look unbelievable.
This is truly a mind bogglingly large opportunity if executed to plan.
General Comments / Chat, page-11589
-
- There are more pages in this discussion • 51 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Featured News
Add RAC (ASX) to my watchlist
(20min delay)
|
|||||
Last
$1.79 |
Change
0.010(0.56%) |
Mkt cap ! $304.2M |
Open | High | Low | Value | Volume |
$1.78 | $1.80 | $1.78 | $106.4K | 59.41K |
Buyers (Bids)
No. | Vol. | Price($) |
---|---|---|
1 | 600 | $1.78 |
Sellers (Offers)
Price($) | Vol. | No. |
---|---|---|
$1.83 | 10000 | 2 |
View Market Depth
No. | Vol. | Price($) |
---|---|---|
1 | 600 | 1.780 |
1 | 1690 | 1.775 |
1 | 11200 | 1.770 |
1 | 300 | 1.765 |
1 | 569 | 1.755 |
Price($) | Vol. | No. |
---|---|---|
1.830 | 10000 | 2 |
1.840 | 1400 | 2 |
1.880 | 2351 | 1 |
1.895 | 7800 | 1 |
1.900 | 159 | 1 |
Last trade - 15.57pm 30/09/2024 (20 minute delay) ? |
Featured News
RAC (ASX) Chart |